刘晓霞 (副研究员,硕士生导师)

       副研究员,药理学博士,硕士生导师。从事肿瘤基础及临床转化研究,围绕肿瘤微环境代谢重编程调控肿瘤恶性进展的机制研究及新型治疗策略的探索。以第一(共同)作者及通迅(共同)作者发表SCI 文章10余篇,其中包含 Nucleic Acids Res, eBiomedicine, Redox Biology, Advanced Science, Journal for ImmunoTherapy of Cancer, Int. J. Biol. Sci, Mol Oncol 等。申请发明专利3项,其中授权2项。先后主持国家自然科学基金1项,广东省自然科学基金-青年提升项目1项,广东省自然科学基金面上项目3项,中国博士后特别资助和面上项目各1项等。研究方向1:饮食干预对肿瘤微环境代谢调控和协同抗肿瘤药物的分子机制和疗效研究;研究方向2:肿瘤微环境代谢重编程对结直肠癌恶性进展的分子机制及新型治疗策略的探索。
教育经历:
(1) 2009-09 至 2014-06, 南方医科大学, 药理学 (硕博连读), 博士
(2) 2005-09 至 2009-06, 湖南中医药大学, 药物制剂, 学士
博士后工作经历:
(1) 2015-08 至 2018-08, 中山大学
科研与学术工作经历:
(1) 2018-09 至今, 中山大学, 附属第六医院, 副研究员
(2) 2014-07 至 2015-07, 南方医科大学, 珠江医院, 助理研究员

代表性论文代表性项目荣誉
1.Yan Q#, Fang X#, Liu X#, Guo S, Chen S, Luo M, Lan P, Guan XY. Loss of ESRP2 Activates TAK1-MAPK Signaling through the Fetal RNA-Splicing Program to Promote Hepatocellular Carcinoma Progression. Adv Sci (Weinh). 2024 Jan;11(1):e2305653. 
2.Liu X#, Peng S#, Tang G, et al. Fasting-mimicking diet synergizes with ferroptosis against quiescent, chemotherapy-resistant cells. EBioMedicine. 2023;90:104496. doi:10.1016/j.ebiom.2023.104496 
3.Zhu M#, Bai L#, Liu X#, et al. Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages. Journal for ImmunoTherapy of Cancer 2022;10:e005610 
4.Peng S, Li Y, Huang M, Tang G, Xie Y, Chen D, Hu Y, Yu T, Cai J, Yuan Z, Wang H, Wang H, Luo Y*, Liu X*. Metabolomics reveals that CAF-derived lipids promote colorectal cancer peritoneal metastasis by enhancing membrane fluidity. Int J Biol Sci. 2022;18(5):1912-1932. 
5.Xie L, Huang R, Huang H, Liu X*, Yu J. Transcriptomics and Metabolomics Identify Drug Resistance of Dormant Cell in Colorectal Cancer. Front Pharmacol. 2022; 13:879751.  
6.Peng S, Chen D, Cai J, Yuan Z, Huang B, Li Y, Wang H, Luo Q, Kuang Y, Liang W, Liu Z, Wang Q, Cui Y, Wang H, Liu X*. Enhancing cancer-associated fibroblast fatty acid catabolism within a metabolically challenging tumor microenvironment drives colon cancer peritoneal metastasis. Mol Oncol. 2021;15(5):1391-1411. 
7.Liu X#, Zhang Y#, Lu W#, Han Y#, Yang J, Jiang W, You X, Luo Y, Wen S, Hu Y, Huang P. Mitochondrial TXNRD3 confers drug resistance via redox-mediated mechanism and is a potential therapeutic target in vivo. Redox Biol. 2020; 36:101652. 
8.Liu X#, Zhang Y, Han Y, Lu W, Yang J, Tian J, Sun P, Yu T, Hu Y, Zhang H, Huang P, Liu P. Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD-L1 and predicts poor prognosis in B-cell lymphoma. Mol Oncol. 2020;14(5):1028-1044. 
9.Wang L, Yang Q, Peng S, Liu X. The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells. Onco Targets Ther. 2019; 12:5359-5373.  
10.Liu X, Wang L, Jiang W, Lu W, Yang J, Yang W. B cell lymphoma with different metabolic characteristics show distinct sensitivities to metabolic inhibitors. J Cancer. 2018;9(9):1582-1591. 
11.Cen B, Liao W, Wang Z, Gao L, Wei Y, Huang W, He S, Wang W, Liu X*, Pan X*, Ji A*. Gelofusine Attenuates Tubulointerstitial Injury Induced by cRGD-Conjugated siRNA by Regulating the TLR3 Signaling Pathway. Mol Ther Nucleic Acids. 2018; 11:300-311. 
12.Liu X#, Wang W#, Samarsky D, Liu L, Xu Q, Zhang W, Zhu G, Wu P, Zuo X, Deng H, Zhang J, Wu Z, Chen X, Zhao L, Qiu Z, Zhang Z, Zeng Q, Yang W, Zhang B, Ji A. Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA. Nucleic Acids Res. 2014;42(18):11805-17. 
13.Liu X, Liu L, Xu Q, Wu P, Zuo X, Ji A. MicroRNA as a novel drug target for cancer therapy. Expert Opin Biol Ther. 2012;12(5):573-80.